Do you like investing with a stock's momentum? For ideas on how to start your search, we ran a screen on outperforming names.
We began by screening the biotech industry for stocks outperforming the market, with over 20% return over the last quarter. We then screened these names for those with bullish trends in shares shorted, with significant decreases in shares shorted month-over-month.
Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.
We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.
Do you think these stocks will outperform like short sellers expect? Use this list as a starting point for your own analysis.
1. Dendreon Corp. (DNDN): Engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. Performance over the last quarter at 51.60%. Shares shorted have decreased from 34.77M to 32.32M over the last month, a decrease which represents about 1.69% of the company's float of 145.39M shares.
2. Micromet, Inc. (MITI): Engages in the discovery, development, and commercialization of antibodies for the treatment of cancer, inflammation, and autoimmune diseases. Performance over the last quarter at 109.33%. Shares shorted have decreased from 7.40M to 6.30M over the last month, a decrease which represents about 1.22% of the company's float of 90.32M shares.
3. Regeneron Pharmaceuticals, Inc. (REGN): Develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. Performance over the last quarter at 92.30%. Shares shorted have decreased from 7.46M to 6.59M over the last month, a decrease which represents about 1.22% of the company's float of 71.38M shares.
4. VIVUS Inc. (VVUS): Engages in the development and commercialization of therapeutic products for underserved markets in the United States. Performance over the last quarter at 145.41%. Shares shorted have decreased from 16.25M to 15.60M over the last month, a decrease which represents about 1.16% of the company's float of 55.93M shares.
*Short data sourced from Yahoo Finance, all other data sourced from Finviz.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
